Study of the long-term immune response after pertussis vaccinatio
- Conditions
- PertussisVaccinationcellular immunityhumoral immunityIn dutch:KinkhoestVaccinatiecellulaire immuniteithumorale immuniteit
- Registration Number
- NL-OMON29115
- Lead Sponsor
- ational Institute for Public Health and the Environment (RIVM)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
• Good general health;
• 8-9 years of age;
Exclusion Criteria
• Present evidence of serious disease(s) demanding immunosuppressive medical treatment, like corticosteroids,
that might interfere with the results of the study. Treatment within the 3 months before the study (chronic infection,
clotting disorder, genetic disorder);
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • To assess pertussis specific IgG antibody levels in serum to determine the effects of a preadolescent aP booster vaccination and determine whether there is a difference in IgG levels between wP and aP primed children at 8-9 years of age;<br /><br>• To assess memory B- and T-cell responses against the various B. pertussis proteins to determine the effects of a preadolescent aP booster vaccination and determine whether there is a difference between wP and aP primed children at 8-9 years of age.
- Secondary Outcome Measures
Name Time Method • To assess pertussis specific IgG-subclasses and -avidity;<br /><br>• To measure serum specific IgG-antibodies, -subclasses and -avidity and memory B- and T-cell responses against the other vaccine components (Diphtheria, Tetanus, Polio, Mumps, Measles and Rubella);<br /><br>• To measure serum specific IgG-antibodies, -subclasses and -avidity against other vaccine components from the NIP;<br /><br>• To measure IgA- and IgE- antibodies in serum against the proteins of B. pertussis and other vaccine components from the NIP.